S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
New CBOE “special perk” helps traders target income every weekend (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
New CBOE “special perk” helps traders target income every weekend (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
New CBOE “special perk” helps traders target income every weekend (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
New CBOE “special perk” helps traders target income every weekend (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 

Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA)

$1.30
-0.10 (-7.17%)
(As of 12/5/2023 ET)
Compare
Today's Range
$1.28
$1.39
50-Day Range
$1.26
$1.81
52-Week Range
$1.12
$2.55
Volume
24.16 million shs
Average Volume
20.74 million shs
Market Capitalization
$2.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
73.7% Upside
$2.25 Price Target
Short Interest
Bearish
17.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Ginkgo Bioworks in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$22.37 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.37) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

768th out of 948 stocks

Biological Products, Except Diagnostic Industry

122nd out of 147 stocks


DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Ginkgo Bioworks (NYSE:DNA) Trading 3.1% Higher
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 5.8%
Where Will Ginkgo Bioworks Be in 5 Years?
Ginkgo Bioworks: A Long Way To Go
Ginkgo Bioworks: More Revenue Issues
Preview: Ginkgo Bioworks Holdings's Earnings
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,292
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+73.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-2,104,930,000.00
Net Margins
-272.30%
Pretax Margin
-275.85%

Debt

Sales & Book Value

Annual Sales
$314.99 million
Book Value
$0.89 per share

Miscellaneous

Outstanding Shares
2,118,437,000
Free Float
1,799,612,000
Market Cap
$2.74 billion
Optionable
Optionable
Beta
1.18
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" DNA shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

4 analysts have issued 12-month target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.25 to $3.00. On average, they expect the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 73.7% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2023?

Ginkgo Bioworks' stock was trading at $1.69 on January 1st, 2023. Since then, DNA stock has decreased by 23.4% and is now trading at $1.2950.
View the best growth stocks for 2023 here
.

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 222,910,000 shares, a drop of 5.5% from the October 31st total of 235,940,000 shares. Based on an average daily trading volume, of 19,520,000 shares, the short-interest ratio is presently 11.4 days. Currently, 17.2% of the shares of the company are short sold.
View Ginkgo Bioworks' Short Interest
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our DNA earnings forecast
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its earnings results on Wednesday, November, 8th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). The business earned $55.43 million during the quarter, compared to the consensus estimate of $46.47 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 36.36% and a negative net margin of 272.30%.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.38%), ARK Investment Management LLC (8.68%), Sumitomo Mitsui Trust Holdings Inc. (2.80%), Schroder Investment Management Group (0.35%), Charles Schwab Investment Management Inc. (0.35%) and Welch & Forbes LLC (0.33%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -